Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension.

Autor: Nasim MT; Department of Medical and Molecular Genetics, King's College London, School of Medicine, Guy's Hospital, London, UK., Ogo T, Ahmed M, Randall R, Chowdhury HM, Snape KM, Bradshaw TY, Southgate L, Lee GJ, Jackson I, Lord GM, Gibbs JS, Wilkins MR, Ohta-Ogo K, Nakamura K, Girerd B, Coulet F, Soubrier F, Humbert M, Morrell NW, Trembath RC, Machado RD
Jazyk: angličtina
Zdroj: Human mutation [Hum Mutat] 2011 Dec; Vol. 32 (12), pp. 1385-9. Date of Electronic Publication: 2011 Oct 11.
DOI: 10.1002/humu.21605
Abstrakt: Heterozygous germline mutations of BMPR2 contribute to familial clustering of pulmonary arterial hypertension (PAH). To further explore the genetic basis of PAH in isolated cases, we undertook a candidate gene analysis to identify potentially deleterious variation. Members of the bone morphogenetic protein (BMP) pathway, namely SMAD1, SMAD4, SMAD5, and SMAD9, were screened by direct sequencing for gene defects. Four variants were identified in SMADs 1, 4, and 9 among a cohort of 324 PAH cases, each not detected in a substantial control population. Of three amino acid substitutions identified, two demonstrated reduced signaling activity in vitro. A putative splice site mutation in SMAD4 resulted in moderate transcript loss due to compromised splicing efficiency. These results demonstrate the role of BMPR2 mutation in the pathogenesis of PAH and indicate that variation within the SMAD family represents an infrequent cause of the disease.
(© 2011 Wiley Periodicals, Inc.)
Databáze: MEDLINE
Externí odkaz: